Prostate Cancer International is
for 2011 by Great NonProfits
A videotaped expert commentary by Dr. Johann de Bono on the Medscape Oncology web site (with transcript) discusses four therapies (three now approved in the USA) that have recently demonstrated a survival benefit in the treatment of metastatic, castration-resistant prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, cabazitaxel, radium-223, sipuleucel-T | Leave a Comment »
Abiraterone acetate (Zytiga®) has been approved for clinical use in European Union nations, according to a media release from Johnson & Johnson issued earlier today. This final approval by the European Commission follows an earlier recommendation for approval issued by the European Medicines Agency (EMEA) at the end of July.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, approval, Europe | Leave a Comment »
According to a media release issued by Johnson & Johnson late last week, after a priority review, Health Canada has approved abiraterone acetate (Zytiga™) in combination with prednisone for the treatment of men with metastatic, castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone acetate, Canada, Zytiga | Leave a Comment »
Some readers may be interested in in reading a commentary by John Carroll on the FierceBiotech web site, where he discusses whether MDV3100 is going to be able to “match up” to abiraterone acetate — always assuming that MDV3100 can also show a survival benefit in men with metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, mCRPC, MDV3100 | 2 Comments »
On Tuesday this week, three papers about abiraterone acetate were published in the on-line version of the Journal of Clinical Oncology. These articles are reports of data previously presented at various clinical/scientific meetings, but at least they are now available in a peer-reviewed journal.
Filed under: Drugs in development, Uncategorized | Tagged: abiraterone acetate, castration-resistant prostate cancer, CRPC | 14 Comments »
There were probably over 100 posters related to prostate cancer presented at the ASCO meeting today (Sunday, May 31), so you will have to pardon us for not even attempting to report on all this vast variety of data. Rather, we have attempted to select out the papers that seem to offer the most interesting [...]
Filed under: Diagnosis, Drugs in development, Risk | Tagged: abiraterone acetate, PCA3 | Leave a Comment »
According to a media release from Cougar Biotechnology, a second Phase III clinical trial of abiraterone acetate started today — for men with castration-resistant prostate cancer (CRPC) who have not received chemotherapy.
Filed under: Drugs in development | Tagged: abiraterone acetate, CRPC, Phase III | 10 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site